Hanyu advances plan to double Wuhan peptide capacity
Chinese peptide manufacturer Hanyu Pharmaceutical has secured shareholder approval for a planned RMB380 million (approximately $57 million) expansion of its Wuhan manufacturing site, advancing a project designed to double annual peptide production capacity.
Shareholders approved the investment on November 12, according to meeting resolutions published the following day.
The project would add 10,000 kg of annual peptide-drug manufacturing capacity, increasing the company's stated Wuhan capacity from 10,000 to 20,000 kg per year once completed.
Originally announced in October, the expansion involves fitting out an existing reserved building and modifying another at Hanyu's Wuhan site. The investment includes more than 200 pieces of process and analytical equipment, including peptide synthesizers, cleavage systems, preparative chromatography equipment and freeze-dryers.
The shareholder vote removes an important corporate approval requirement but does not establish that construction has begun. The original investment proposal also identified environmental approval as a necessary step, and the latest announcement does not confirm that it has been obtained.
Hanyu has not provided a new commissioning date or evidence that the additional capacity is available for commercial production.
The project represents a potential doubling of Wuhan's peptide manufacturing capacity rather than an immediate increase in market supply.